Somatosensory Disorders: Clinical Trials

43 trials for Somatosensory Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

29 completed, 3 recruiting, 3 terminated, 3 unknown. 43 Phase 2, 4 Phase 3, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 243Completed 29, Recruiting 3, Terminated 3, Unknown 3, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Suspended 1
Phase 34Completed 2, Recruiting 2
Phase 12Completed 1, Unknown 1

Follow Somatosensory Disorders: new trials by email Literature Review of Somatosensory Disorders trials Research Report on Somatosensory Disorders

Trials (filtered) newest first · largest first

All 43 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effectiveness of Oxitard Gel Versus Physiotherapeutic and Pharmacological Interventions in Alleviating Oral Submucous Fibrosis: A Phase-II Randomized Control Trial
Herbal Formulation, Shekar's appliance, Multivitamin/Mineral supplements - Oral and Maxillofacial Conditions
Phase 2Not yet recruitingDow University of Health Sciences202026-11-152026-11-06
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
VMD-3866 Gel, Placebo Gel - Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain
Phase 2RecruitingVM Therapeutics LLC162025-12-122026-10-21
Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy
Ozone therapy, Oxygen (placebo) - Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia
Phase 2 / Phase 3RecruitingBernardino Clavo, MD, PhD422025-02-072026-09-18
Gut Microbiome Profiles in Patients With Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544).
Ozone therapy, Oxygen (placebo) - Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia
Phase 2 / Phase 3RecruitingBernardino Clavo, MD, PhD422025-02-072026-09-25
Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia
Remifentanil, Remifentanil+ Placebo, Remifentanil +ultra-low dose naloxone - Hyperalgesia
Phase 2TerminatedUniversity of California, Irvine82023-02-252026-06-04
Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in Humans
Active Cannabis, Placebo Cannabis - Cannabis, Pain
Phase 2SuspendedNew York State Psychiatric Institute162021-08-012026-09-24
Post-operative Analgesic Effect of Oral Nefopam
Oral nefopam, Placebo - Postoperative Pain After a Total Knee Arthroplasty
Phase 2Active not recruitingHospices Civils de Lyon502021-06-292026-11-16
Repeated Cannabis Administration on Experimental Pain and Abuse Liability
Active Cannabis, Placebo Cannabis - Cannabis, Pain
Phase 2CompletedNew York State Psychiatric Institute102021-06-012025-08-08
Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent
Voriconazole (topical), Topical Sterile Water Placebo Group - Pain, Thermal Injury
Phase 2WithdrawnKenneth Hargreaves2018-06-152018-12-17
Can DFN-15 Terminate Migraine With Allodynia?
DFN-15, Placebo - Migraine With Aura, Migraine Without Aura
Phase 2CompletedHartford Hospital512018-05-092019-04-16
Effect of High-dose Naloxone Following Third Molar Extraction
Naloxone, Normal Saline - Healthy Subjects, Hyperalgesia
Phase 2Completedmads u werner232017-10-122024-02-22
Low-Dose Naltrexone and Acetaminophen Combination in the Treatment of Chronic Low Back Pain (ANODYNE-4)
Low-dose naltrexone and acetaminophen combination, Placebo - Chronic Low Back Pain, Lumbar Radiculopathy
Phase 2CompletedAllodynic Therapeutics, Inc122017-08-152021-04-14
Using Intranasal Midazolam (INM) and Lidocaine for Uncooperative Children
Midazolam, Lidocaine-Midazolam, Placebo - Burning Nose
Phase 2 / Phase 3CompletedLatakia University632017-06-012018-11-05
Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
DS-1971a, placebo, pregabalin - Neuropathic Pain, Diabetes
Phase 2WithdrawnDaiichi Sankyo2016-02-012016-07-27
Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia During a Burn Injury
Naloxone, Normal saline - Healthy Subjects
Phase 2Completedmads u werner802016-02-012024-02-23
Effect of High-dose Naloxone Infusion on Pain and Hyperalgesia in Patients Following Groin-Hernia Repair.
Target-controlled naloxone-infusion, Placebo - Central Nervous System Sensitization, Pain
Phase 2CompletedCopenhagen University Hospital, Rigshospitalet92015-11-112024-02-22
ST266 in UV-induced Inflammation
ST266 immediate, ST266 delayed - Skin Burns
Phase 2CompletedNoveome Biotherapeutics, formerly Stemnion102015-03-012019-05-15
The Effect of Hyperbaric Oxygen Therapy on Inflammatory Parameters Induced by a Heat Injury Model
Hyperbaric oxygen - Secondary Hyperalgesia, Inflammation
Phase 2CompletedCopenhagen University Hospital, Rigshospitalet262015-02-012019-06-21
Preoperative Intraarticular Injection of Methylprednisolone in Patients Scheduled for Total Knee-arthroplasty
Methylprednisoloneacetate, Lidocaine, sodium chloride - Knee Joint Osteoarthrosis, Hyperalgesia
Phase 2CompletedCopenhagen University Hospital, Rigshospitalet482014-10-012016-06-06
Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients
Minocycline, Placebo, Questionnaires - Colorectal Cancer
Phase 2CompletedM.D. Anderson Cancer Center1222013-11-012020-03-17

Showing 20 of 43. Sign in to see all of them.

Narrower conditions

Hyperalgesia (28)  ·  Pain (18)  ·  Paresthesia (10)  ·  Hypesthesia (9)  ·  Neuralgia (8)  ·  Chronic Pain (5)  ·  Agnosia (4)  ·  Anxiety Disorders (3)  ·  Marijuana Abuse (3)  ·  Burns (2)  ·  Depression (2)  ·  Herpes Zoster (2)  ·  Neuralgia, Postherpetic (2)  ·  Pain, Postoperative (2)  ·  Peripheral Nervous System Diseases (2)

Broader conditions

Nervous System Diseases (43)  ·  Neurologic Manifestations (43)  ·  Pathological Conditions, Signs and Symptoms (43)  ·  Sensation Disorders (43)  ·  Signs and Symptoms (43)  ·  Neuromuscular Diseases (9)  ·  Pain (9)  ·  Mental Disorders (7)  ·  Peripheral Nervous System Diseases (7)  ·  Wounds and Injuries (5)  ·  Neurobehavioral Manifestations (4)  ·  Pathologic Processes (4)  ·  Perceptual Disorders (4)  ·  Central Nervous System Diseases (3)

Interventions

Saline Solution (4)  ·  Dextromethorphan (2)  ·  Lidocaine (2)  ·  Naloxone (2)  ·  Nefopam (2)  ·  Oxygen (2)  ·  Remifentanil (2)  ·  rofecoxib (2)  ·  AZD2066 (1)  ·  Amantadine (1)  ·  Blood Specimen Collection (1)  ·  Botulinum Toxins, Type A (1)  ·  Bupivacaine (1)  ·  Carvedilol (1)  ·  Celecoxib (1)

Sponsors

Copenhagen University Hospital, Rigshospitalet (3)  ·  National Institute of Dental and Craniofacial Research (NIDCR) (3)  ·  Bernardino Clavo, MD, PhD (2)  ·  Brigham and Women's Hospital (2)  ·  New York State Psychiatric Institute (2)  ·  Novalar Pharmaceuticals, Inc. (2)  ·  mads u werner (2)  ·  Aegera Therapeutics (1)  ·  Allodynic Therapeutics, Inc (1)  ·  AstraZeneca (1)  ·  Azad University of Medical Sciences (1)  ·  Cantonal Hospital of St. Gallen (1)  ·  Center for Medicinal Cannabis Research (1)  ·  Columbia Northwest Pharmaceuticals (1)  ·  Daiichi Sankyo (1)

Countries

United States (25)  ·  Denmark (5)  ·  Canada (3)  ·  France (2)  ·  Spain (2)  ·  Bulgaria (1)  ·  Iran (1)  ·  Pakistan (1)  ·  Romania (1)  ·  South Korea (1)  ·  Switzerland (1)  ·  Syria (1)  ·  United Kingdom (1)

Top investigators

Bernardino Clavo, MD, PhD (2)  ·  Bradley K Taylor, M.Sc., Ph.D. (2)  ·  Christine N. Sang, MD, MPH (2)  ·  Mads U Werner, MD, DMSc (2)  ·  Annette Toledano, M.D. (1)  ·  Ariana Nelson, MD (1)  ·  Arifulla Khan, MD (1)  ·  Bahman Jabbari, MD (1)  ·  Biljana Lilja (1)  ·  Brett Stacey (1)  ·  Cathy Eng, MD, BA (1)  ·  Christopher E White, MD (1)

Results publications

PMID 16275600, PMID 21300053, PMID 23741350, PMID 24052307, PMID 26305798, PMID 11576045, PMID 15560360, PMID 16202520, PMID 22365565, PMID 23063945, PMID 23671631, PMID 24012952, PMID 25227929, PMID 26000320, PMID 26554360, PMID 27739142, PMID 30274305, PMID 30915992, PMID 41572235, PMID 8109774

NIH funding

R01NS041503 (2), R21DA050752 (1)